以下文章来源于内分泌早知道 ，作者关注内分泌的 深度分享内分泌用药经验、病例剖析、指南专业解读并紧跟国内外内分泌领域前沿进展，「每医健」旗下内容平台。 对于2型糖尿病患者来说，外周动脉疾病（PAD）是个不容忽视的"隐形杀手"。它不仅严重影响患者行动能力，更会显著降低生活质 量，甚至增加死亡风险。然而目前临床上能有效改善PAD症状的药物却寥寥无几。 作为GLP- 1受体激动剂的明星药物，司美格鲁肽最初以出色的降糖效果闻名。但随着研究深入，人们发现它更像一个"多面手"——不仅 能控制血糖、减轻体重，还对心血管、肾脏等多个系统都有显著保护作用。更令人振奋的是，早前STRIDE试验的初步数据就显示，每 周注射1.0mg司美格鲁肽，可以明显改善合并PAD的2型糖尿病患者的身体机能和生活质量。 内分泌早知道 . 最新发表在权威期刊《Di a be t e s Ca r e》上的研究给出了更确凿的证据。这项基于STRIDE试验的深入分析采用随机双盲、安慰剂对照 的严格设计，重点探讨了司美格鲁肽对PAD患者的功能改善作用是否在不同特征人群中具有普遍性。这一发现为临床治疗提供了重要参 考。 ▍ 研究目标 1.司美格鲁肽的疗效是 ...

Core Viewpoint - The article emphasizes the significant therapeutic potential of Semaglutide for patients with type 2 diabetes and peripheral artery disease (PAD), highlighting its multifaceted benefits beyond glucose control and weight loss [3][10]. Research Objectives - The study aims to analyze whether the efficacy of Semaglutide is consistent across different clinical characteristics in patients with type 2 diabetes and PAD, focusing on key variables such as diabetes duration, body mass index (BMI), HbA1c levels, and concurrent medication use [5][8]. Research Methodology - The STRIDE trial included 792 patients with symptomatic PAD and type 2 diabetes, employing a randomized, double-blind design over 52 weeks to assess the effects of Semaglutide compared to a placebo [7]. Key Assessment Indicators - The primary endpoint was the improvement in maximum walking distance (MWD) after 52 weeks, with supplementary assessments of pain-free walking distance (PFWD) [9]. Research Results - Semaglutide significantly improved both MWD and PFWD across various patient subgroups, indicating a stable therapeutic effect regardless of patient characteristics [10][12]. - The average weight loss was 4.09 kg, and HbA1c levels decreased by 0.99%, but the benefits for PAD appeared to operate through independent mechanisms [11][12]. Safety Profile - The safety profile of Semaglutide was found to be comparable to that of the placebo, with no new safety concerns identified, and common gastrointestinal reactions and hypoglycemia were evenly distributed among subgroups [13]. Conclusion - Semaglutide is positioned as a breakthrough treatment option for patients with type 2 diabetes and PAD, demonstrating efficacy that extends beyond traditional mechanisms, including improvements in endothelial function and anti-inflammatory effects [16].